SANTA BARBARA, Calif.–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2022 after the market closes on Monday, May 9, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results.
To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13729225. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Motiva MIA®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.
Contacts
Investor/Media Contact:
Raj Denhoy
415-828-1044
Rdenhoy@establishmentlabs.com
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10,…
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol…
LOS ANGELES--(BUSINESS WIRE)--#biohacking--Next Health, the world’s most advanced and comprehensive brand of health optimization and…
PROVIDENCE, R.I., March 31, 2025 /PRNewswire/ -- The Rhode Island Life Science Hub and Brown…
COLOGNE, Germany and SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Medit, a global leader…
HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX:…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
